Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria

American Journal of Tropical Medicine and Hygiene

Volumn 72, Issue 3, 2005, Pages 267-272

  Dzinjalamala, Fraction K ^a   Macheso, Allan ^b   Kublin, James G ^c   Taylor, Terrie E ^d   Barnes, Karen I ^a   Molyneux, Malcom E ^e   Plowe, Christopher V ^f   Smith, Peter J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Management Sciences for Health   (Malawi)

^c UNIVERSITY OF MALAWI   (Malawi)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^f University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; FANSIDAR; FOLIC ACID; BIOLOGICAL MARKER; ENZYME INHIBITOR; PYRIMETHAMINE; SULFADOXINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DEMOGRAPHY; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; FOLIC ACID BLOOD LEVEL; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALAWI; MALE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; TREATMENT FAILURE; ANALYSIS OF VARIANCE; BLOOD; CHILD; CLINICAL TRIAL; DRUG COMBINATION; INFANT; METABOLISM; RISK; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; FOLIC ACID; HUMANS; INFANT; MALARIA, FALCIPARUM; MALAWI; MALE; ODDS RATIO; PYRIMETHAMINE; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 18244404066     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.72.267     Document Type: Article

References (30)

1. WHO Study Group, 1995. WHO vector control for malaria and other mosquito borne diseases. World Health Organ Tech. Rep Ser: 857.
2. Remme JHF, Binka F, Nabarro D, 2001. Toward a framework and indicators for monitoring role back malaria. Am J Trop Med Hyg 64 (suppl): 76-84.
3. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK II, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353: 1965-1967.
4. Peters W, 1997. Chemotherapy and Drug resistance in Malaria. London: Academic Press.
5. Sibley CH, Hyde JE, Sims PFG, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, 2001. Pyrimethamine-sulfadoxine resistance in P. falciparum: what next? Trends Parasitol 17: 582-588.
6. Plowe CV, Cortese JF, Djimde A, Nwanyanu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK, 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176: 1590-1596.
7. Basco LK, Tahar R, Ringwald P, 1998. Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum parasites. Antimicrob. Agents Chemother 42: 1811-1814.
8. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RAG, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for treatment failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone of falciparum malaria. J Infect Dis 185: 380-388.
9. Thompson PE, Werbel LM, 1972. Chemistry and pharmacology. Medicinal Chemistry: Antimalarial Agents. New York: Academic Press.
10. Krungkrai J, Webster HK, Yolhavong Y, 1989. De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum. Mol Microbiol 23: 1254-1262.
11. Stokstad ELR, Koch J, 1967. Folate acid metabolism. Physiol Rev 47: 83-116.
12. Russell RM, Ismail-Beigi F, Alfrasiabi K, Rahimifar, Pourkamal D, Ronaghy H, 1976. Folate levels among various populations in central Iran. Am J Clin Nutr 29: 794-798.
13. White NJ, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol. 18: 458-464.
14. Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, Niare-Doumbo S, Coulibaly D, Kone AK, Cissoko Y, Tekete M, Fofana B, Dicko A, Diallo DA, Wellems TE, Kwiatkowski D, Plowe CV, 2003. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558-563.
15. Kinyanjui SM, Mberu EK, Winstanley PA, Jacobus DP, Watkins WM, 1999. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitro activity against Plasmodium falciparum and a non-antifolate mode of action of the prodrug. Am J Trop Med Hyg 60: 943-947.
16. Watkins WM, Sixsmith DG, Chulay JD, Spencer HC, 1985. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Mol Biochem Parasitol 14: 55-61.
17. van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM, 1995. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. Trans R Soc Trop Med Hyg 89: 672-676.
18. Gail K, Herms V, 1969. Influence of pteroylglutamic acid (folic acid) on parasite density (Plasmodium falciparum) in pregnant women in West Africa. Z Trop Parasitol 20: 440-450.
19. World Health Organization, 2002. Monitoring Antimalarial Resistance. Geneva: World Health organization. Report of a WHO consultation, WHO/CDS/CSR/EPH/2002.17.
20. Winstanley PA, Watkins WM, Newton CRJC, Nevill C, Mberu E, Warns PA, Waruiru CM, Mwangi IN, Warrell DA, Marsh K, 1992. The disposition of oral and intramuscular pyrimethamine/sulfadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol 33: 143-148.
21. Plowe CV, Djimde A, Bouare M, Doumbo OK, Wellems TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 52: 565-568.
22. Baird JK, Jones TR, Danudirgo EW, Annis BA, Bangs MJ, Basri H, Purnomo, Masbar S, 1991. Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am J Trop Med Hyg 45: 65-76.
23. Wang P, Brobey RK, Horii T, Sims PF, Hyde JE, 1999. Utilization of exogenous folate in the human malaria parasite Plasmodium falciparum and its critical role in antifolate drug synergy. Mol Microbiol 32: 1254-1262.
24. U.S. Department of Agriculture, Agricultural Research Service 1999. USDA Nutrient Database for Standard Reference, Release 13. Nutrient Data Lab Home Page, http://www.nal.usda.gov/fnic/foodcomp
25. Diem K, Lentner C, eds, 1970. Scientific Tables. Seventh edition. Basel, Switzerland: Geigy Pharmaceuticals.
26. Tsui JC, Nordstrom JW, 1990. Folate status of adolescence: effects of folic acid supplementation. J Am Diet Assoc 90: 1551-1556.
27. Wang P, Wang Q, Aspinall TV, Sims PF, Hyde JE, 2004. Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium faciparum. Mol Microbiol 51: 1425-1438.
28. Nzila A, Mberu E, Bray P, Kokwaro G, Winstanley P, Marsh K, Ward S, 2003. Chemosensitization of Plasmodium falciparum by Probenecid in vitro. Antimicrob Agents Chemother 47: 2108-2112.
29. Chanarin I, 1979. The Megaloblastic Anaemias. Oxford, United Kingdom: Blackwell Scientific Publications.
30. Gregory JF, 1997. Bio-availability of folate. Eur J Clin Nutr 51: 554-559.